No Prescription |
 |
 | ||
|
LOPID Generic Gemfibrozil |
|
| ||
No Prescription » Prescription Drugs 10 » LOPID Generic Gemfibrozil Lopid is used for: Treating high blood cholesterol and triglyceride. Gemfibrozil helps reduce cholesterol and triglycerides (fatty acids) in the blood. High levels of these types of fat in the blood are associated with an increased risk of atherosclerosis (clogged arteries).Gemfibrozil is used to treat very high cholesterol and triglyceride levels in people with pancreatitis.Gemfibrozil is also used to lower the risk of stroke heart attack or other heart complications in people with high cholesterol and triglycerides who have not been helped by other treatment methods.Lopid is prescribed along with a special diet for treatment of people with very high levels of serum triglycerides (a fatty substance in the blood) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.This drug can also be used to reduce the risk of coronary heart disease in people who have failed to respond to weight loss diet exercise and other triglyceride- or cholesterol-lowering drugs. Buy LOPID Generic Gemfibrozil and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About LOPID Generic Gemfibrozil: Product Type: Prescription Drugs 10 LOPID ( Generic Gemfibrozil ) LOPID (Generic Gemfibrozil) Generic Gemfibrozil 300MG 2 x 100 Capsules 300MG 100 Capsules 300MG 4 x 100 Capsules 600mg 2 x 100 Capsules 600mg 30 Tablets 600mg 100 Capsules 600mg 4 x 100 Capsules Generic Gemfibrozil LOPID
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
